Notice: This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RTTR vs. TYRA, TRDA, PRTA, CDMO, EOLS, RAPP, ESPR, ANAB, MBX, and CVACShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Tyra Biosciences (TYRA), Entrada Therapeutics (TRDA), Prothena (PRTA), Avid Bioservices (CDMO), Evolus (EOLS), Rapport Therapeutics (RAPP), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), MBX Biosciences (MBX), and CureVac (CVAC). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Tyra Biosciences Entrada Therapeutics Prothena Avid Bioservices Evolus Rapport Therapeutics Esperion Therapeutics AnaptysBio MBX Biosciences CureVac Tyra Biosciences (NASDAQ:TYRA) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Do analysts prefer TYRA or RTTR? Tyra Biosciences presently has a consensus price target of $31.00, suggesting a potential upside of 121.43%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, TYRA or RTTR? Tyra Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Do insiders and institutionals have more ownership in TYRA or RTTR? 84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor TYRA or RTTR? Ritter Pharmaceuticals received 271 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 73.81% of users gave Tyra Biosciences an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTyra BiosciencesOutperform Votes3173.81% Underperform Votes1126.19% Ritter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Is TYRA or RTTR more profitable? Ritter Pharmaceuticals' return on equity of 0.00% beat Tyra Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Tyra BiosciencesN/A -24.56% -23.31% Ritter Pharmaceuticals N/A N/A -162.05% Does the media refer more to TYRA or RTTR? In the previous week, Tyra Biosciences had 1 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 1 mentions for Tyra Biosciences and 0 mentions for Ritter Pharmaceuticals. Tyra Biosciences' average media sentiment score of 0.50 beat Ritter Pharmaceuticals' score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Overall Sentiment Tyra Biosciences Positive Ritter Pharmaceuticals Neutral Which has better earnings and valuation, TYRA or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTyra BiosciencesN/AN/A-$69.13M-$1.61-8.70Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A SummaryTyra Biosciences beats Ritter Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.00M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-6.0910.5990.1317.20Price / SalesN/A196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book39.005.094.784.78Net Income-$10.13M$151.83M$120.31M$225.60M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.90-3.5%N/A+607.4%$180.00MN/A-6.097TYRATyra Biosciences2.0666 of 5 stars$15.90+1.1%$31.00+95.0%+2.3%$804.54MN/A0.0020TRDAEntrada Therapeutics2.5973 of 5 stars$21.33-1.2%$25.67+20.3%+19.2%$798.17M$129.01M13.63110Gap DownPRTAProthena1.6181 of 5 stars$14.64+4.2%$61.86+322.5%-59.2%$787.78M$91.37M0.00173Analyst ForecastNews CoverageCDMOAvid Bioservices2.4408 of 5 stars$12.30+0.2%$12.25-0.4%+91.9%$784.62M$139.91M0.00371EOLSEvolus3.8214 of 5 stars$12.26-3.2%$23.00+87.6%+9.1%$776.30M$202.09M0.00170Positive NewsRAPPRapport Therapeutics1.5135 of 5 stars$21.17+3.5%$35.00+65.3%N/A$774.40MN/A0.00N/AESPREsperion Therapeutics3.908 of 5 stars$3.82+9.8%$8.17+113.8%-6.0%$752.69M$116.33M-5.97240Analyst ForecastAnalyst RevisionNews CoverageANABAnaptysBio2.3014 of 5 stars$24.59-0.9%$54.64+122.2%-26.6%$748.27M$17.16M0.00100Analyst ForecastMBXMBX BiosciencesN/A$22.29+0.5%$37.25+67.1%N/A$744.93MN/A0.0036Gap DownCVACCureVac4.5753 of 5 stars$3.30+6.5%$10.00+203.0%-29.8%$738.80M$58.18M5.641,172News CoverageGap Down Related Companies and Tools Related Companies Tyra Biosciences Competitors Entrada Therapeutics Competitors Prothena Competitors Avid Bioservices Competitors Evolus Competitors Rapport Therapeutics Competitors Esperion Therapeutics Competitors AnaptysBio Competitors MBX Biosciences Competitors CureVac Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTTR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
